Skip to main content
Premium Trial:

Request an Annual Quote

Applied BioCode, Diatherix Ink Partnership, Supply Agreement

NEW YORK (GenomeWeb) - Applied BioCode and Diatherix Laboratories today announced that they have signed a partnership and supply agreement to develop multiplex molecular diagnostic panels for laboratory testing.

Applied BioCode, a privately held biotechnology company, develops, manufactures, and markets barcoded magnetic beads (BMB) and detection systems to facilitate development of highly multiplexed nucleic acid or protein detection assays. Diatherix Laboratories, located in the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama, operates as an independent, CAP-accredited clinical laboratory that provides advanced multiplex molecular diagnostic services.

Diatherix will utilize its TEM-PCR technology with Applied BioCode's BMB technology and detection systems to develop highly sensitive multiplex molecular diagnostic panels for infectious disease laboratory testing.

"We are pleased to partner with Applied BioCode for their barcoded magnetic bead technology," Diatherix CEO Dennis Grimaud said in a statement. The technology, he added, will allow Diatherix "to reduce the development timeframe to bring new multiplex test panels to market and enhance the sensitivity of our molecular diagnostic panels."

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.